Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT05910177RecruitingPhase 2
Pre-surgery treatment for cervical neuroendocrine cancer with immunotherapy
This Phase 2 trial tests giving camrelizumab plus chemotherapy (etoposide and cisplatin) before surgery for certain cervical neuroendocrine cancers. It aims to shrink the tumor and improve outcomes by treating cancer early rather than waiting until after surgery.
Fuzhou, FujianAges 18–75 - NCT05913427RecruitingPhase 2
Progesterone added to chemo for adrenal cancer that spread
This Phase 2 trial tests whether adding progesterone to standard chemotherapy improves outcomes for people with adrenal cortical carcinoma (ACC) that is locally advanced or has spread and cannot be removed with surgery. It also checks whether the treatment is safe and tolerable.
BresciaAges 18 years+ - NCT05913388RecruitingPhase 2
Testing a new drug plus pembrolizumab versus pembrolizumab alone
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Portland, OregonAges 18 years+ - NCT05917106Recruiting
Testifying methylomics blood test for new kidney cancer monitoring
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
Nanjing, JiangsuAges Any age - NCT05918510Recruiting
Blood and tumor study for virus markers in throat cancer
This study looks at virus-related markers and tiny gene regulators (microRNAs) in tumor tissue from people with certain throat cancers caused by human papilloma virus (HPV). It’s observational, meaning it does not change your treatment, but results may help doctors better understand these cancers and how they behave.
RomeAges 18 years+ - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT05920863RecruitingPhase 2
Lenvatinib, immunotherapy, plus liver artery treatment before surgery
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hangzhou, ZhejiangAges 18–75 - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05931393RecruitingPhase 2
Cabozantinib retreatment after it helped, in kidney cancer study
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
Dallas, TexasAges 18 years+ - NCT05935189Recruiting
Hepatocellular cancer tissue registry for Armenian patients
This study builds a tissue (sample) registry for people with liver cancer to help researchers learn more and improve future care. It’s mainly about confirming your diagnosis and collecting consent for using your biopsy tissue.
YerevanAges Any age - NCT05937438RecruitingPhase 1/Phase 2
Radiation then immunotherapy after esophagus surgery
This trial studies giving radiation right after esophagus surgery, followed by immunotherapy, to keep the cancer from coming back. It is for people with a specific type and stage of esophageal squamous cell carcinoma.
Hefei, AnhuiAges 18–75 - NCT05945875RecruitingPhase 1
Dual scans to find head and neck cancer spread
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
Nashville, TennesseeAges 19 years+ - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT05953961Recruiting
90Y radiation compared with microwave ablation for small liver cancer
This trial compares two procedures to treat a small, single liver tumor that cannot be surgically removed. It aims to see which treatment works better for people with low blood protein (albumin), which can affect healing and outcomes.
New Orleans, LouisianaAges 18 years+ - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT05956587RecruitingPhase 2
Testing two study drugs for advanced lung cancer and other tumors
This Phase 2 study tests a combination of two experimental medicines in people with advanced or metastatic solid cancers, including non-small cell lung cancer and nasopharyngeal cancer. It aims to see whether the drugs can shrink tumors and improve outcomes, while carefully checking safety and eligibility.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05962242RecruitingPhase 2
HPV-tested de-escalated radiation for HPV-related throat cancer
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
Miami, FloridaAges 18 years+ - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT05962892Recruiting
Study of thyroid cancer return risk after heat ablation
This study looks at what makes papillary thyroid cancer come back after a heat-based treatment called thermal ablation. It may help doctors better predict recurrence risk and guide follow-up after treatment.
BeijingAges 18 years+ - NCT05963464Recruiting
Marker-assisted breast surgery for hard-to-feel tumors
This study tests a small implantable “marker” system (used to help doctors find the tumor or lymph node during breast surgery) for people with breast or lymph node areas that can’t be felt. It may help surgery planning and accuracy when the cancer can’t be easily located by touch.
MilanAges 18–90 - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT05970666RecruitingPhase 2
TACE plus immunotherapy and VEGF drug for unresectable liver cancer
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
Xiamen, FujianAges 18–75
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,181 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.